Square Pharmaceuticals (SQURPHARMA) Q1 24/25 earnings summary

Executive summary

• Consolidated net revenue for Q1 FY2024-25 was Tk. 17.75 billion, nearly flat year-over-year, with net profit after tax at Tk. 6.09 billion, a slight decrease from Tk. 6.00 billion in the prior year.

• Standalone net revenue was Tk. 14.02 billion, down from Tk. 15.65 billion year-over-year, with net profit after tax at Tk. 4.02 billion, compared to Tk. 5.07 billion last year.

• Earnings per share (EPS) for the consolidated group was Tk. 6.87, up from Tk. 6.77 year-over-year; standalone EPS was Tk. 4.53, down from Tk. 5.72.

Financial highlights

• Consolidated gross profit margin was 50.3%, slightly down from 51.4% year-over-year.

• Consolidated operating profit was Tk. 5.56 billion, down from Tk. 6.37 billion year-over-year.

• Consolidated income from investments rose to Tk. 1.46 billion from Tk. 1.09 billion year-over-year.

• Net asset value (NAV) per share increased to Tk. 149.76 from Tk. 142.05 year-over-year.

• Net operating cash flow per share (NOCF) dropped to Tk. 3.89 from Tk. 9.54 year-over-year due to absence of one-off insurance and credit collections seen last year.

Outlook and guidance

• Management notes continued business growth and positive asset performance, with no significant seasonal or cyclical sales variations expected.

• No significant post-period events or changes in accounting policies were reported.